Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field studyExpect to ...
Seeking Alpha

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose ...
Business Insider

I-Mab announces givastomig as lead program

I-Mab (IMAB) highlighted its strategic outlook for 2025 and a re-prioritization of resources, with a focus on advancing its lead program, givastomig, a CLDN18.2 x 4-1BB bispecific antibody, targeting ...
Nasdaq

I-Mab Prioritizes Givastomig as Lead Program in Strategic Shift

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener I-MAB ( (IMAB)) has ...
Yahoo Finance

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

- Data Support PKU and Hunter Syndrome Clinical Trials and PNH Program - BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, ...
EurekAlert!

Lundquist Institute start-up Vitalex Biosciences awarded grant from NIAID/NIH

The Lundquist Institute (TLI) start-up company, Vitalex Biosciences, has been awarded an SBIR Phase 2 grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National ...
Morningstar

I-Mab’s Partner AbbVie Discontinues a Key CD47 Program; Reducing I-Mab’s FVE to $32.50

Yesterday, multiple media sources reported that AbbVie is stopping its phase 1 clinical trial of lemzoparlimab (“lemzo”) as part of a combination treatment for myelodysplastic syndromes, or MDS, and ...
News Medical

New study finds maternal vaccine and monoclonal antibody effective against RSV in infants

In a recent article published in The Lancet Regional Health Journal, researchers compared the impact and cost-effectiveness of maternal vaccination (MV) to long-acting monoclonal antibody (la-mAB) ...
Sustainable Brands

UNESCO MAB Recognizes 7 Young Scientists for Work on Ecosystems, Natural Resources, Biodiversity

The International Coordinating Council of UNESCO’s Man and the Biosphere (MAB) Program has named the recipients of its 2017 Young Scientists Awards and the Michel Batisse Award for Biosphere Reserve ...
Forbes

UNESCO’s Man And Biosphere World Changing Program, That Needs More Awareness

The UNESCO Man and the Biosphere (MAB) Program is a remarkable initiative carried out by resourceful, dedicated communities around the world who develop multi-pronged, sustainable ecosystems with ...
KRQE Blogs

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

ROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...
The Victoria Advocate

I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

ROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...